Evidence map›Paper›PMID 32714434›Full record

ArticleInfectious agents and cancer2020

Variation in KSHV prevalence between geographically proximate locations in Uganda.

Angela Nalwoga, Emily L Webb, Claudios Muserere, Belinda Chihota, Wendell Miley, Nazzarena Labo, Alison Elliott, Stephen Cose, Denise Whitby, Robert Newton

Abstract read
In one paragraph

Article in Infectious agents and cancer, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 10 papers.

0numbers the graph read from it
0cells of the map it votes in
10citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

10 citing papers in PubMed.

  1. Trial
  2. Article
  3. Review
  4. Article
  5. Article
  6. Article
  7. Article
  8. Article
  9. Article
  10. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors.

Angela NalwogaMRC/UVRI and LSHTM Uganda Research Unit, Entebbe, Uganda.ORCID 0000-0001-8259-4735
Emily L WebbLondon School of Hygiene & Tropical Medicine, London, UK.
Claudios MuserereLondon School of Hygiene & Tropical Medicine, London, UK.
Belinda ChihotaLondon School of Hygiene & Tropical Medicine, London, UK.
Wendell MileyViral Oncology Section, AIDS and Cancer Virus Program, Leidos Biomedical Research, Inc., Frederick National Laboratory for Cancer Research, Frederick, MD USA.
Nazzarena LaboViral Oncology Section, AIDS and Cancer Virus Program, Leidos Biomedical Research, Inc., Frederick National Laboratory for Cancer Research, Frederick, MD USA.
Alison ElliottMRC/UVRI and LSHTM Uganda Research Unit, Entebbe, Uganda.
Stephen CoseMRC/UVRI and LSHTM Uganda Research Unit, Entebbe, Uganda.
Denise WhitbyViral Oncology Section, AIDS and Cancer Virus Program, Leidos Biomedical Research, Inc., Frederick National Laboratory for Cancer Research, Frederick, MD USA.
Robert NewtonUniversity of York, York, UK.

Funding

Environmental determinants of KSHV transmission in rural UgandaR01CA239588 · NCI · UNIVERSITY OF COLORADO DENVER · PI ROBERT, NEWTON, SABOURIN, KATHERINE R · 2019 to 2023
$2.6M
CCR NIH HHS HHSN261200800001CMedical Research Council MC_UU_00027/5Medical Research Council MR/R010161/1NCI NIH HHS HHSN261200800001ENCI NIH HHS R01 CA239588Wellcome Trust
6 · The paper itself

Abstract

Kaposi's sarcoma-associated herpesvirus (KSHV) transmission within endemic areas may vary. KSHV seroprevalence has been studied by different groups of researchers using different methods, making it difficult to make direct comparisons. Here we show results on KSHV seroprevalence using the same laboratory method from four different but geographically proximate populations in Uganda. Blood samples from the urban Entebbe Mother and Baby Study (EMaBS), the rural General Population Cohort (GPC), the fishing community Lake Victoria Island Intervention Study on Worms and Allergy related Diseases (LaVIISWA) and the high-risk sexual behaviour Good Health for Women Project (GHWP), were tested for IgG antibody levels to K8.1 and ORF73 recombinant proteins using ELISA. All adult participants of the EMaBS study and the GHWP were women, while the GPC (54% female) and LaVIISWA (52% female) studies had both males and females. EMaBS children were all 5 years of age while their mothers were 14 to 47 years of age. GHWP women were 15 to 45 years old, LaVIISWA participants were 1 to 72 years old while GPC participants were 1 to 103 years old. KSHV seropositivity varied in the different populations. In children aged 5 years, EMaBS had the lowest prevalence of 15% followed by GPC at 35% and LaVIISWA at 54%. In adult women, seropositivity varied from 69% (EMaBS) to 80% (LaVIISWA) to 87% (GPC) to 90% (GHWP). The reasons for the variation in prevalence are unclear but may reflect differences in the prevalence of cofactors between these four geographically proximate populations.

Indexed as

KSHVSeroprevalenceUgandaVarious populations

Identifiers

PMID32714434
PMCPMC7376633

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.